5-[2-(3-Cyclopropyl-4-fluorophenyl)pyridin-3-yl]pyrazolo[1,5-a]pyrimidine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 5-[2-(3-Cyclopropyl-4-fluorophenyl)pyridin-3-yl]pyrazolo[1,5-a]pyrimidine
• 英文别名: 5-[2-(3-cyclopropyl-4-fluorophenyl)pyridin-3-yl]pyrazolo[1,5-a]pyrimidine
• 化学式: C₂₀H₁₅FN₄
• 分子量: 330.4
• InChiKey: GQUUEJUNZJHASN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  25
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  43.1
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• [EN] 2,3-DISUBSTITUTED PYRIDINE COMPOUNDS AS TGF-BETA INHIBITORS AND METHODS OF USE<br/>[FR] COMPOSÉS DE PYRIDINE 2,3-DISUBSTITUÉS UTILISÉS COMME INHIBITEURS DE TGF-BÊTA ET PROCÉDÉS D'UTILISATION
  申请人：RIGEL PHARMACEUTICALS INC

  公开号：WO2015157093A1

  公开（公告）日：2015-10-15

  The invention described herein comprises compounds of formula (IV) and a method of treating cancer comprising administering to a subject having cancer one of the compounds in conjunction with another therapeutic treatment of cancer. The compounds (IV) inhibit signaling by a member of the TGF-β superfamily such as Nodal or Activin.

  本发明涉及的化合物包括公式（IV）的化合物，以及一种治疗癌症的方法，包括向患有癌症的受试者施用其中一种化合物，结合另一种癌症治疗方法。这些化合物（IV）抑制TGF-β超家族成员如Nodal或Activin的信号传导。
• GDF-8 Inhibitors
  申请人：Rigel Pharmaceuticals, Inc.

  公开号：US20140107073A1

  公开（公告）日：2014-04-17

  Described are GCF-8 inhibitors of the formula (I), and pharmaceutically acceptable salts thereof, wherein n, R 1 , R 2 , R 5 , R 6 , X and Z are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for inhibiting GDF-8 in a cell and methods for treating a patient suffering from a disease or disorder, wherein the patient would therapeutically benefit from an increase in mass or strength of muscle tissue.

  本文描述了式（I）的GCF-8抑制剂及其药学上可接受的盐，其中n、R1、R2、R5、R6、X和Z在此定义。还提供了包含这些化合物的制药组合物。这些化合物和组合物在抑制细胞中的GDF-8和治疗患有疾病或障碍的患者的方法中有用，其中患者从增加肌肉组织的质量或力量中获得治疗上的益处。
• 2,3-disubstituted pyridine compounds as TGF-beta inhibitors and methods of use
  申请人：Rigel Pharmaceuticals, Inc.

  公开号：US10233170B2

  公开（公告）日：2019-03-19

  The invention described herein comprises compounds of formula (IV) and a method of treating cancer comprising administering to a subject having cancer one of the compounds in conjunction with another therapeutic treatment of cancer. The compounds (IV) inhibit signaling by a member of the TGF-β superfamily such as Nodal or Activin.

  本文所述的发明包括式（IV）化合物和一种治疗癌症的方法，该方法包括给患有癌症的受试者施用其中一种化合物，并结合另一种癌症治疗方法。化合物（IV）抑制 TGF-β 超家族成员如 Nodal 或 Activin 的信号转导。
• 2,3-Disubstituted pyridine compounds as TGF-β inhibitors and methods of use
  申请人：Rigel Pharmaceuticals, Inc.

  公开号：US10858335B2

  公开（公告）日：2020-12-08

  The invention described herein comprises compounds and a method of treating cancer comprising administering to a subject having cancer one of the compounds in conjunction with another therapeutic treatment of cancer. The compounds inhibit signaling by a member of the TGF-β superfamily such as Nodal or Activin.

  本文所述的发明包括化合物和一种治疗癌症的方法，该方法包括向患有癌症的受试者施用其中一种化合物，并结合另一种癌症治疗方法。 这些化合物抑制 TGF-β 超家族成员如 Nodal 或 Activin 的信号转导。
• GDF-8 INHIBITORS
  申请人：Rigel Pharmaceuticals, Inc.

  公开号：EP2903978A1

  公开（公告）日：2015-08-12